Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    ... (KPT-330) that we can give to patients with leukemia or MDS, when it is combined with fludarabine and cytarabine. The goal of the ... leukemia (MPAL) and myelodysplastic syndrome (MDS). SECONDARY OBJECTIVES: To characterize the pharmacokinetics of selinexor, ...

    Clinical Trial last updated 04/28/2016 - 9:48am.

  2. T-cell Depleted Alternative Donor Transplantation

    ... an alternative (unrelated and mismatched related) donor. The secondary objectives include evaluation of engraftment , immune ... myelodysplastic syndromes (MDS) Phase:  ...

    Clinical Trial last updated 04/29/2016 - 3:38pm.

  3. RIC Transplant Using Haplo Donors

    ... estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, ... myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/29/2016 - 10:52am.

  4. GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t(8;21), t(15;17), inv 16). Secondary AML ALL/LL in 1st remission with clinical or molecular features ...

    Clinical Trial last updated 04/29/2016 - 12:40pm.

  5. HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st remission AML in 1st relapse or > than or = to 2nd ...

    Clinical Trial last updated 04/29/2016 - 3:18pm.

  6. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st remission AML in 1st relapse or > 2nd remission ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.

  7. Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... with bone marrow blasts <5%); or Secondary acute myeloid leukemia on the basis of prior MDS in hematologic ...

    Clinical Trial last updated 05/02/2016 - 11:10am.

  8. Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... achieve CR with primary induction chemotherapy . Secondary AML, defined as AML related to antecedent myeloid neoplasm or ...

    Clinical Trial last updated 04/29/2016 - 1:00pm.

  9. A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

    ... . Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of <75 Giga (10^9) per liter (Gi/L) ... free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease ...

    Clinical Trial last updated 04/27/2016 - 1:28pm.

  10. CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

    ... . To determine how often primary graft failure and secondary graft failure occurs in the children, adolescents and young adults ... aplastic anemia myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/28/2016 - 8:36am.